Breast Cancer | Norton Healthcare

Indication: Breast Cancer

A Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing the Activity of Paclitaxel Plus Trastuzumab Plus Lapatinib to Paclitaxel Plus Trastuzumab Plus Placebo in Women with ErbB2 Overexpressing Metastatic Breast Cancer

Drug Study

Principal Investigator: John Hamm, M.D.
Norton Cancer Institute

Sponsor: GlaxoSmithKline

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.